Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 4/20 | 0.34 |
| ▸ | FNTB | P49356 | 4/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17894246 | 0.90 | CYP11B2 (0.39) | CYP11B2CYP11B1NR3C2NR3C1FNTA | |
| SCHEMBL13563925 | 0.88 | CYP11B2 (0.45) | CYP11B2CYP11B1NR3C2NR3C1CYP19A1 | |
| SCHEMBL1039260 | 0.87 | CYP11B2 (0.45) | CYP11B2CYP11B1NR3C2NR3C1CYP19A1 | |
| SCHEMBL14562264 | 0.84 | CYP11B2 (0.40) | CYP11B2CYP11B1NR3C2NR3C1CYP19A1 | |
| SCHEMBL17894300 | 0.80 | SLC6A9 (0.35) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL3465188 | 0.78 | GABRA1 (0.36) | CYP11B2CYP11B1LMNASMN1; SMN2 | |
| SCHEMBL19763074 | 0.77 | CYP11B2 (0.43) | CYP11B2CYP11B1NR3C2NR3C1CYP19A1 | |
| SCHEMBL17894243 | 0.76 | CYP11B2 (0.42) | CYP11B2CYP11B1NR3C2NR3C1FNTA | |
| SCHEMBL17894240 | 0.74 | CYP11B2 (0.38) | CYP11B2CYP11B1NR3C2NR3C1FNTA | |
| SCHEMBL3466250 | 0.74 | CYP11B2 (0.44) | CYP11B2CYP11B1NR3C2CYP19A1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278969-B2 | Organic compounds | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140357621-A1 | Organic Compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2256118-B1 | Condensed imidazolo derivatives for the inhibition of aromatase and the treatment of aldosterone related diseases | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8835646-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20130287789-A1 | Organic Compounds | NOVARTIS AG (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-1919916-B1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-8314097-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20120277215-A1 | Organic Compounds | RECORDATI AG (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2270011-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2256118-A1 | Condensed imidazolo derivatives for the inhibition of aromatase | Novartis AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| EP-1919916-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | Novartis AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049616-A1 | Organic compounds | RECORDATI AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2007024945-A1 | CONDENSED IMIDAZOLO DERIVATIVES FOR THE INHIBITION OF ALDOSTERONE SYNTHASE AND AROMATASE | NOVARTIS AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049616-A1 | Organic compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885NR3C2 61/4885 |
| US-20130287789-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885NR3C2 61/4885 |
| US-20120277215-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885NR3C2 61/4885 |
| US-20140357621-A1 | Organic Compounds | CYP19A1, CYP17A1, HSD17B11 | CYP11B2 14/4885CYP11B1 5/4885NR3C2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.